|Table of Contents|

Comparison of the application of automatic immunohistochemistry and first-generation sequencing in the detecting of isocitrate dehydrogenase 1 mutation in human glioma

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2022 04
Page:
599-602
Research Field:
Publishing date:

Info

Title:
Comparison of the application of automatic immunohistochemistry and first-generation sequencing in the detecting of isocitrate dehydrogenase 1 mutation in human glioma
Author(s):
LIN Li; ZHU Xiangfeng; FU Ping; WANG Qiushi; XIAO Hualiang
Department of Pathology,Daping Hospital,Army Medical University,Chongqing 400042,China.
Keywords:
glioma; IDH1; first-generation sequencing; automatic immunohistochemistry
PACS:
R739.41
DOI:
10.3969/j.issn.1672-4992.2022.04.008
Abstract:
Objective:To compare the advantages and disadvantages between automatic immunohistochemistry and first-generation sequencing in detecting the mutation of isocitrate dehydrogenase 1 (IDH1) gene in human glioma,and to provide an effective method for clinical detection of IDH1 gene mutation in glioma.Methods:Ninety-nine paraffin-embedded surgical specimens of gliomas were collected.Immunohistochemical staining of IDH1-R132H was performed by automatic immunohistochemical staining machine.Then the mutation status of IDH1 gene was identified by three pathologists according to the staining results.At the same time,the whole genome DNA of the 99 paraffin-embedded glioma tissues was extracted,and the mutation status of IDH1-R132H gene was detected by ABI3500 sequencer.Cohen's Kappa test was used to compare the consistency of two detection methods in the diagnosis of IDH1 gene mutation in glioma.Results:Automated immunohistochemical staining showed that IDH1 mutation occurred in 22 of 99 gliomas.First-generation sequencing showed that 20 of 99 gliomas had IDH1 mutations,and 2 cases were not detected due to poor DNA quality.Cohen's Kappa test confirmed that automatic immunohistochemistry and first-generation sequencing had high consistency in detecting IDH1 gene mutation in glioma(Cohen's Kappa=0.94).Conclusion:Automatic immunohistochemistry and first-generation sequencing have a high degree of consistency in detecting IDH1 gene status in glioma.Automatic immunohistochemistry is the first choice and first-generation sequencing is suitable for negative cases by immunohistochemistry.

References:

[1] CHIEN LN,GITTLEMAN H,OSTROM QT,et al.Comparative brain and central nervous system tumor incidence and survival between the United States and Taiwan based on population-based registry［J］.Front Public Health,2016,4:151.
[2]STEPANENKO AA,CHEKHONIN VP.Recent advances in oncolytic virotherapy and immunotherapy for glioblastoma:a glimmer of hope in the search for an effective therapy［J］.Cancers,2018,10 (12):492.
[3]STUPP R,BRADA M,VAN DEN BENT MJ,et al.High-grade glioma:ESMO Clinical Practice Guidelines for diagnosis,treatment and follow-up［J］.Ann Oncol,2014,25(3):93-101.
[4]LOUIS DN,PERRY A,REIFENBERGER G,et al.The 2016 World Health Organization Classification of Tumors of the Central Nervous System:a summary［J］.Acta Neuropathol,2016,131(6):803-820.
[5]HARTMANN C,MEYER J,BALSS J,et al.Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age:a study of 1,010 diffuse gliomas［J］.Acta Neuropathol,2009,118(4):469-474.
[6]YAN H,PARSONS DW,JIN G,et al.IDH1 and IDH2 mutations in gliomas［J］.N Engl J Med,2009,360(8):765-773.
[7]Cancer Genome Atlas Research Network,BRAT DJ,VERHAAK RG,et al.Comprehensive,integrative genomic analysis of diffuse lower-grade gliomas［J］.N Engl J Med,2015,372(26):2481-2498.
[8]ECKEL-PASSOW JE,LACHANCE DH,MOLINARO AM,et al.Glioma groups based on 1p/19q,IDH,and TERT promoter mutations in tumors［J］.N Engl J Med,2015,372(26):2499-2508.
[9]VUONG HG,ALTIBI AMA,DUONG UNP,et al.TERT promoter mutation and its interaction with IDH mutations in glioma:Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data［J］.Crit Rev Oncol Hematol,2017,120:1-9.
[10]王玉环.探讨免疫组化检测脑胶质瘤 IDH1 及应用［J］.中国卫生标准管理，2018,9(15):125-127. WANG YH.Investigation on IDH1 in immunohistochemical detection of glioma and its application［J］.China Health Standard Management,2018,9(15):125-127.
[11]CAIRNS RA,MAK TW.Oncogenic isocitrate dehydrogenase mutations:mechanisms,models,and clinical opportunities［J］.Cancer Discov,2013,3:730-741.
[12] IZQUIERDO-GARCIA JL,VISWANATH P,ERIKSSON P,et al.IDH1 mutation induces reprogramming of pyruvate metabolism［J］.Cancer Res,2015,75(15):2999-3009.
[13]TURKALP Z,KARAMCHANDANI J,DAS S.IDH mutation in glioma:new insights and promises for the future［J］.JAMA Neurol,2014,71(10):1319-1325.
[14]BUJKO M,KOBER P,MATYJA E,et al.Prognostic value of IDH1 mutations identified with PCR-RFLP assay in glioblastoma patients［J］.Mol Diagn Ther,2010,14(3):163-169.
[15] BACK M,JAYAMANNE DT,BRAZIER D,et al.Influence of molecular classification in anaplastic glioma for determining outcome and future approach to management［J］.J Med Imaging Radiat Oncol,2019,63(2):272-280.
[16]WAITKUS MS,DIPLAS BH,YAN H.Biological role and therapeutic potential of IDH mutations in cancer［J］.Cancer Cell,2018,34(2):186-195.

Memo

Memo:
-
Last Update: 1900-01-01